Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro

被引:372
作者
Zava, DT [1 ]
Duwe, G [1 ]
机构
[1] CALIF PUBL HLTH FDN, CANC RES DIV, BERKELEY, CA 94704 USA
来源
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | 1997年 / 27卷 / 01期
关键词
D O I
10.1080/01635589709514498
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Experimental and epidemiologic studies support the view that soyfoods prevent cancer as well as diseases and symptoms associated with estrogen deficiency. Recent research suggests that the isoflavonoid genistein, a phytoestrogen found in abundance in soyfoods, may be one of the principal molecular components responsible for these health benefits. In this study we investigated the effects of a broad physiologically relevant concentration range of genistein on estrogen receptor (ER) binding, induction of the estrogen-regulated antigen pS2, and cell proliferation rate in ER(+) and ER(-) human breast cancer cells grown in vitro. Dose response to genistein was compared with that of estradiol, tamoxifen, and several other structurally similar iso- and bioflavonoids (e.g., equol, kaempferol, and quercetin). Our results revealed that genistein has potent estrogen agonist and cell growth-inhibitory actions over a physiologically achievable concentration range (10 nM-20 mu M). Other flavonoids over the same concentration range were good estrogen agonists and poor cell growth inhibitors (equol) or poor estrogen agonists and potent growth inhibitors (kaempferol and quercetin). The growth-inhibitory actions of flavonoids were distinctly different from those of triphenyl antiestrogens like tamoxifen. In summary, our results reveal that genistein is unique among the flavonoids tested, in that if has potent estrogen agonist and cell growth-inhibitory actions over a physiologically relevant concentration range.
引用
收藏
页码:31 / 40
页数:10
相关论文
共 61 条
  • [1] ADLERCREUTZ CHT, 1995, J NUTR, V125, pS757, DOI 10.1093/jn/125.3_Suppl.757S
  • [2] AVILA MA, 1994, CANCER RES, V54, P2424
  • [3] THE EVOLUTION OF MENOPAUSAL SYMPTOMS
    AVIS, NE
    KAUFERT, PA
    LOCK, M
    MCKINLAY, SM
    VASS, K
    [J]. BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1993, 7 (01): : 17 - 32
  • [4] BORS W, 1990, METHOD ENZYMOL, V186, P343
  • [5] PROGRESS IN UNDERSTANDING BREAST-CANCER - EPIDEMIOLOGICAL AND BIOLOGICAL INTERACTIONS
    BOYLE, P
    LEAKE, R
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1988, 11 (02) : 91 - 112
  • [6] ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE
    COBLEIGH, MA
    BERRIS, RF
    BUSH, T
    DAVIDSON, NE
    ROBERT, NJ
    SPARANO, JA
    TORMEY, DC
    WOOD, WC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (07): : 540 - 545
  • [7] CONSTANTINOU A, 1990, CANCER RES, V50, P2618
  • [8] COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027
  • [9] DILORENZO D, 1991, CANCER RES, V51, P4470
  • [10] EMSTER VL, 1987, JNCI, V79, P949